Objective: This is the final report of a phase III randomized study to evaluate whole-brain
radiotherapy (WBRT) in primary therapy of primary CNS lymphoma (PCNSL) after a median …

Background: High-dose methotrexate (MTX) and whole brain radiation therapy (WBRT)
prolong survival in primary CNS lymphoma (PCNSL) patients but have been associated with …

Background High-dose methotrexate is the standard of care for patients with newly
diagnosed primary CNS lymphoma. The role of whole brain radiotherapy is controversial …

Objective: To assess the efficacy and safety of a preradiation chemotherapy regimen in
patients with primary CNS lymphoma (PCNSL), with emphasis on long-term outcomes …

2501 Background: MTX-based chemoradiotherapy is effective in PCNSL, but carries a risk of
severe neurotoxicity (NT), especially in the elderly. In a phase II single arm study, R-MPV-A …

Whole brain radiotherapy (WBRT) has been increasingly omitted as the first treatment of
primary central nervous system lymphoma (PCNSL) because of neurotoxicity risks …

Purpose This study evaluates the efficacy and toxicity of whole-brain radiation therapy
(WBRT) as salvage therapy for immunocompetent patients who failed initial high-dose …

Background: Historically, high-dose methotrexate (HD-MTX) plus consolidation
chemotherapy and/or whole brain radiotherapy (WBRT) has been the gold standard on …

Background The treatment of primary CNS lymphoma (PCNSL) comprises high dose
methotrexate (HDMTX) based chemotherapy followed by whole brain radiotherapy (WBRT) …

Purpose We previously reported a series of patients treated with high-dose methotrexate
(MTX)-based chemotherapy, with or without whole brain radiotherapy. The purpose of this …